We are pleased to share the BC Pharmacare announcement that Duodopa is now listed on formulary effective Dec. 10, 2020, which means there will no longer be a cap on the number of BC Duodopa patients per year. The BC criteria for access to Duodopa is now similar to other provinces.

Treatments like this are a primary focus of our upcoming webinar, Progressing Parkinson’s Disease – A discussion on Device Aided Therapies. You can register to attend this webinar, which takes place on Dec. 14, 2020.

From a press release by the Parkinson Society British Columbia:

British Columbia’s Ministry of Health has announced today that they have removed the yearly limit on the number of British Columbians who can receive Duodopa® therapy. Previously, BC PharmaCare only covered five individuals per year for this therapy, resulting in a two-year waitlist for Parkinson’s patients experiencing debilitating symptoms.

Duodopa® is used to treat patients with advanced Parkinson’s disease who have severe and disabling motor symptoms that cannot be well controlled with available combinations of medications. It is a levodopa and carbidopa drug combination delivered in the form of a gel through an intestinal pump.

Read the full press release here.